Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.69 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435175 | 0.82 | DGAT1 (1.00) | DGAT1SOAT2CYP2C9 | |
| SCHEMBL12045609 | 0.76 | DGAT1 (0.88) | DGAT1SOAT2CYP2C9 | |
| SCHEMBL462112 | 0.75 | DGAT1 (0.87) | DGAT1SOAT2 | |
| SCHEMBL1443381 | 0.72 | DGAT1 (0.60) | DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL410047 | 0.71 | DGAT1 (0.67) | DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL410046 | 0.71 | DGAT1 (0.67) | DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL10198182 | 0.71 | DGAT1 (0.67) | DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL374783 | 0.70 | DGAT1 (1.00) | DGAT1SOAT2CYP2C9SOAT1KCNH2 | |
| SCHEMBL15445010 | 0.69 | DGAT1 (0.73) | DGAT1SOAT2CYP2C9 | |
| SCHEMBL12060223 | 0.68 | DGAT1 (0.72) | DGAT1SOAT2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2408766-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010107765-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT2 6/4885CYP2C9 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.